A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Public ClinicalTrials.gov record NCT03149003. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.
Study identification
- NCT ID
- NCT03149003
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 221 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2017 (Actual)
- Primary completion
- Aug 30, 2021 (Actual)
- Completion
- Aug 30, 2021 (Actual)
- Last update posted
- Nov 15, 2023
2017 – 2021
United States locations
- U.S. sites
- 37
- U.S. states
- 21
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Center for Neurosciences | Tucson | Arizona | 85718 | — |
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| UCSD- Moores Cancer Center | La Jolla | California | 92093 | — |
| Kaiser Permanente Los Angeles Medical Center | Los Angeles | California | 90027 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Neuro-Oncology/ US Irvine Medical Center | Orange | California | 92868 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| John Wayne Cancer Institute | Santa Monica | California | 90404 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Piedmont brain tumor center | Atlanta | Georgia | 30309 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Kentucky / Department of Internal Medicine / Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Abbott Northwestern Hospital | Minneapolis | Minnesota | 55407 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Dent Neurosciences Research Center | Amherst | New York | 14226 | — |
| Weill Cornell Medicine | New York | New York | 10021 | — |
| Columbia University Medical Center/ Neurological Institute of NY | New York | New York | 10032 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| University of Toledo | Toledo | Ohio | 43606 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Medical Center (UPMC) | Pittsburgh | Pennsylvania | 15232 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| University of Tennessee Academic Medical Center Cancer Institute | Knoxville | Tennessee | 37920 | — |
| Texas Oncology Austin Midtown | Austin | Texas | 78705 | — |
| Baylor Scott and White | Dallas | Texas | 75246 | — |
| Houston Methodist | Houston | Texas | 77030 | — |
| Mischer Neuroscience Associates/Memorial Hermann Hospital | Houston | Texas | 77030 | — |
| Renovatio Clinical | The Woodlands | Texas | 77380 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Swedish Medical Center | Seattle | Washington | 98122 | — |
| University of Wisconsin Hospital | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03149003, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 15, 2023 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03149003 live on ClinicalTrials.gov.